H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Climb Bio (CLYM) with a Buy rating and $9 price target The firm views Climb Bio as a “disruptive innovator” in the field of B cell-mediated autoimmune diseases. Comparable valuations “hint at considerable upside potential” for the shares, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: